OCA
BDTX icon

Octagon Capital Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

Octagon Capital Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-594,000
Closed -$2.58M – 37
2024
Q3 		$2.58M Buy
+594,000
New +$3.23M 0.4% 33

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Octagon Capital Advisors's BDTX Position: Q4 2024 in Review

Octagon Capital Advisors sold out of Black Diamond Therapeutics (BDTX) in Q4 2024, closing a stake of 594,000 shares — an estimated $2.58M sold.

Octagon Capital Advisors first reported a position in BDTX in Q3 2024 and held it in 1 quarter. The position peaked at $2.58M in Q3 2024. 87 funds tracked by Wall St. Rank hold BDTX as of Q4 2024.

  • Octagon Capital Advisors reported no remaining Black Diamond Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 594,000 Black Diamond Therapeutics shares in Q4 2024, an estimated $2.58M.
  • Octagon Capital Advisors first reported a position in Black Diamond Therapeutics in Q3 2024 and held it in 1 quarter.
  • Octagon Capital Advisors's Black Diamond Therapeutics position peaked at $2.58M in Q3 2024.
  • 87 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2024.

Based on Octagon Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.